首页> 外文期刊>Avian Diseases >Load of Challenge Marek's Disease Virus DNA in Blood as a Criterion for Early Diagnosis of Marek's Disease Tumors
【24h】

Load of Challenge Marek's Disease Virus DNA in Blood as a Criterion for Early Diagnosis of Marek's Disease Tumors

机译:血液中挑战性马立克氏病病毒DNA的负载量作为早期诊断马立克氏病肿瘤的标准

获取原文
获取原文并翻译 | 示例
           

摘要

Outbreaks of Marek's disease (MD) in vaccinated flocks still occur sporadically and lead to economic losses. Unfortunately, adequate methods to predict MD outbreaks are lacking. In the present study, we have evaluated whether high load of challenge MD virus (MDV) DNA in peripheral blood could aid in the early diagnosis of MD and in monitoring efficacy of vaccines against MD. One experiment was conducted to simulate field conditions by combining various vaccines (turkey herpesvirus [HVT] and HVT + MDV serotype 2 [SB1]) and challenge viruses (GA, Md5, and 648A). Vaccine efficacy among our experimental groups ranged from 13.3% to 94.2%. Each chicken was sampled three times during the length of the experiment (3, 5, and 15 wk postchallenge [wpc]), and gross lesions were evaluated in chickens that died and at termination of the experiment. DNA was extracted from whole blood and buffy coats from each sample, and the load of challenge MDV DNA and HVT DNA were quantified by real-time polymerase chain reaction. Chickens that developed MD by the end of the experiment had higher load of challenge MDV DNA (threshold cycle [Ct] glyceraldehyde-3-phosphate dehydrogenase [GAPDH]/Ct glycoprotein B [gB] ratios of 1.0, 1.04, and 1.05 at 3, 5, and 15 wpc, respectively) than those that did not develop MD (Ct GAPDH/Ct gB ratios of 0.7, 0.69, and 0.46 at 3, 5, and 15 wpc, respectively). However, load of HVT DNA in blood was not correlated with the development of tumors (Ct GAPDH/Ct HVT ratios from 0.04 to 0.10 in both groups). Vaccinated groups with >75% protection had statistically significant less challenge DNA virus (Ct GAPDH/Ct gB ratios of 0.76, 0.70, and 0.45 at 3, 5, and 15 wpc, respectively) than less protected groups (Ct GAPDH/Ct gB ratios of 0.92, 0.97, and 0.85 at 3, 5, and 15 wpc, respectively). No differences in the load of HVT DNA could be found between protected and nonprotected groups at any time point of the study (Ct GAPDH/Ct HVT from 0.05 to 0.09 in both groups). Our results showed that load of challenge MDV DNA but not load of HVT DNA in blood can be used as criterion for early diagnosis of MD.
机译:在疫苗接种的鸡群中,马立克氏病(MD)的暴发仍然零星发生,并导致经济损失。不幸的是,缺少预测MD暴发的适当方法。在本研究中,我们评估了外周血中高负荷的挑战性MD病毒(MDV)DNA是否可以帮助MD的早期诊断和监测针对MD的疫苗的有效性。通过组合各种疫苗(火鸡疱疹病毒[HVT]和HVT + MDV血清型2 [SB1])和攻击病毒(GA,Md5和648A),进行了一项模拟野外条件的实验。我们的实验组中的疫苗效力范围为13.3%至94.2%。在实验过程中(攻击后3、5和15周,每只鸡)进行了3次采样,并评估了死亡和实验终止时的鸡的总体损伤。从每个样本的全血和血沉棕黄层中提取DNA,并通过实时聚合酶链反应对攻击MDV DNA和HVT DNA的负荷进行定量。在实验结束时发育成MD的鸡的攻击MDV DNA负荷较高(在3时,阈值循环[Ct] -3-磷酸甘油醛3脱氢酶[GAPDH] / Ct糖蛋白B [gB]的比率分别为1.0、1.04和1.05),分别比未产生MD的那些(分别在3、5和15 wpc时Ct GAPDH / Ct gB比分别为0.7、0.69和0.46)高出5和15 wpc。但是,血液中HVT DNA的载量与肿瘤的发展无关(两组的Ct GAPDH / Ct HVT比值从0.04到0.10)。接种率> 75%的疫苗接种组的攻击性DNA病毒(Ct GAPDH / Ct gB比率分别为3、5和15 wpc时,Ct GAPDH / Ct gB比率分别为0.76、0.70和0.45)在统计学上显着低于受保护程度较低的组(Ct GAPDH / Ct gB比率)在3、5和15 wpc时分别为0.92、0.97和0.85)。在研究的任何时间点,受保护组和未受保护组之间均未发现HVT DNA载量的差异(两组的Ct GAPDH / Ct HVT均介于0.05至0.09之间)。我们的结果表明,血液中挑战性MDV DNA的负载而不是HVT DNA的负载可以用作MD早期诊断的标准。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号